16 Sep 2025 Nirsevimab (Beyfortus) Now Available
Vaccines for Children (VFC) providers are now welcome to order nirsevimab (Beyfortus) as needed. Nirsevimab (Beyfortus), a monoclonal antibody immunization used to prevent RSV infection in infants and young children, can be administered from October 1, 2025 to March 31, 2026.
Once we receive your nirsevimab orders, our team may adjust order quantities as needed to ensure equitable distribution among patient populations.
Eligibility, Dosage, & Administration
Nirsevimab (Beyfortus) is administered as an intramuscular injection with a single-dose, pre-filled syringe.
Indications
- Infants aged < 8 months and born during or entering their first RSV season
- 50 mg for infants weighing < 5 kg
- 100 mg for infants weighing ≥ 5 kg
- Children 8-19 months who are at increased risk of severe RSV disease and are entering their second RSV season
- 200 mg, administered as two 100 mg injections
Click here to view more information about which children are at increased risk and should be vaccinated during their second season.
Click here to view a flowchart to aid providers in determining the appropriate dose of nirsevimab (Beyfortus) for patients.
Storage & Handling
- Store refrigerated between 36°F to 46°F (2°C to 8°C) through the expiration date.
- After removal from the refrigerator, nirsevimab (Beyfortus) must be used within 8 hours or discarded.
Reporting Adverse Events
Nirsevimab (Beyfortus) is the first immunoglobulin drug product to be included in the VFC program. If nirsevimab (Beyfortus) is administered:
- alone, then suspected adverse events are reported to MedWatch.
- simultaneously with any vaccine, suspected adverse events are reported to the Vaccine Adverse Event Reporting System (VAERS).
- Additional reporting to MedWatch is not needed.